Hypothesis: The SLC30A3-CD33-TREM2 Axis in Alzheimer's Disease: Integrating Zinc Dysregulation, Microglial Function, Lithium Deficiency, and CRISPR-Based Interventions

Comprehensive Summary: The SLC30A3-CD33-TREM2 Axis in Alzheimer's Disease This research presents a novel integrative hypothesis examining the SLC30A3-CD33-TREM2 axis as a critical pathway in Alzheimer's disease (AD) pathogenesis. We propose that dysfunction in zinc transporter 3 (ZnT3), encoded by SLC30A3, particularly through the rare p.Val374Met variant, disrupts zinc homeostasis and synergizes with lithium deficiency to accelerate AD pathology. Our framework connects zinc dysregulation with impaired microglial function through the CD33-TREM2 immune regulatory axis. CD33 acts as an inhibitory receptor suppressing amyloid-beta (Aβ) phagocytosis, while TREM2 promotes clearance mechanisms downstream. Zinc dysregulation stabilizes CD33's inhibitory conformation, and lithium deficiency further disrupts microglial activation states, creating a perfect storm for impaired Aβ clearance and enhanced neuroinflammation. The manuscript introduces innovative CRISPR/Cas9-based therapeutic strategies including gene knockout, CRISPR interference, base editing, and prime editing to modulate this axis. We propose targeted interventions to disrupt CD33 inhibition, correct SLC30A3 variants, and restore metabolic homeostasis. Validation experiments utilizing iPSC-derived microglia and AD mouse models will test this framework. The study highlights lithium deficiency as an environmental risk factor and presents clinical evidence of lithium supplementation improving cognitive scores and biomarker profiles. This work provides a unified mechanism connecting metal ion dysregulation, genetic susceptibility, environmental factors, and microglial dysfunction in AD. The proposed therapeutic approaches offer promising avenues for precision medicine interventions targeting this novel axis in Alzheimer's disease pathogenesis.